Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
Date:6/29/2010

ORLANDO, Fla. and CARLSBAD, Calif., June 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando.  These presentations included two oral talks highlighting data from Isis' Phase 2 study of ISIS 113715 in patients with type 2 diabetes and Isis' Phase 1 study of ISIS-GCGRRx. Isis and collaborators also presented new data from five other programs demonstrating that antisense drugs can approach novel targets to treat metabolic diseases and may provide new therapeutic options for patients.  

In the oral presentation titled "ISIS 113715, a Novel PTP-1B Antisense Inhibitor, Improves Glycemic Control and Dyslipidemia and Increases Adiponectin Levels in T2DM Subjects Uncontrolled on Stable Sulfonylurea Therapy," Dr. Sanjay Bhanot presented the results of a Phase 2 study evaluating ISIS 113715 in patients with type 2 diabetes whose glucose levels were uncontrolled despite being treated with maximum doses of sulfonylureas.  The study produced the following results:

  • Statistically significant reductions in multiple short and intermediate measures of glucose control at the 200 mg/week dose
  • Statistically significant decrease of approximately 11 mg/dL in LDL Cholesterol
  • Reduction in body weight that was preceded by a statistically significant increase in circulating adiponectin, supporting the role of PTP-1B in the regulation of body weight
  • No clinically significa
    '/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
2. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
3. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
4. LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
5. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010
8. New Publication Highlights 2-Year Durability and Effectiveness of Macroplastique(R)
9. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
(Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, ... hot flashes that often accompany menopause, new research suggests. ... of menopausal women, said Dr. Taraneh Shirazian, an assistant professor ... School of Medicine at Mount Sinai Hospital in New York ... hot flashes a day, and she added that hot flashes ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3
... Coaches, trainers focus on prevention, better treatment for ... -- "Getting your bell rung." "A dinger." "Knocking ... a serious problem -- a concussion. , But ... are getting a lot better at spotting a ...
... barometer - gas prices go up, major ... market trend to stay home, shop online, REDMOND, Wash., ... offering over 30,000 supplements at,savings up to 50% today announced that ... quarters of 2008 as people change shopping habits to,offset today,s high ...
... Holmes,(Amex: HH ) today announced the sale ... Claims Evaluation Division (CED), a unit providing,independent medical ... for use in evaluating claims., The sale ... purchase,price of approximately $5.6 million. In one transaction, ...
... prices, biofuels, and climate change places 1.7,billion people ... risk of hunger, warns,anti-poverty agency ActionAid., WASHINGTON, ... in Hokkaido, Japan, ActionAid launches a new report, ... Global Food Crisis and What,They Can Do to ...
... NavigatorMD, Inc., a leading,benefits intelligence, software ... of Value-Based Plan Design development, announced,the addition ... Development and,Sales., Norris brings 24 years ... including market development and management. As Director ...
... - Thyroid cancer that has spread to distant sites has ... blood vessel formation can slow disease progression in some patients, ... Texas M. D. Anderson Cancer Center reports in the July ... . , The investigational drug, motesanib diphosphate, is a VEGF ...
Cached Medicine News:Health News:Playing It Safe With High School Sports 2Health News:Playing It Safe With High School Sports 3Health News:Playing It Safe With High School Sports 4Health News:Photo: VitaminLife.com Sees Internet Sales Up 40% in Major Metro Markets as Gas Crisis Looms; Shopping Behaviors Change as People Conserve Gas 2Health News:Hooper Holmes Announces Sale of Claims Evaluation Division 2Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:Marshall Norris Joins NavigatorMD as Director of Business Development and Sales 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4
... Stryker Threaded Dilator System ... another choice for drilling ... provide compaction reaming versus ... of bone within the ...
... The USS Sports Medicine Knot Pusher is a ... arthroscopic surgery. The Knot Pusher is utilized in ... and retrieving. The two piece shaft allows the ... slot for knot pushing. The ring handle allows ...
... Arthroscopy Scissor is ideal for excising soft tissue ... in the joint. The serrated edge on the ... as hold tissue within the jaws for more ... right jaw curvatures, are the perfect tools for ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
Medicine Products: